Healthcare systems need to deliver more care while controlling rising costs — even as they grapple with funding models that contribute to inefficiencies, unnecessary medical procedures, and inconsistent quality levels. As this Viewpoint explores, value-based contracting (VBC) is transforming healthcare by linking payment for treatments, technologies, and services to their outcomes. This leads to insurers paying for results, providers delivering cost-effective and personalized care, and patients more easily accessing innovative therapies.
In the last 20 years, healthcare systems have focused on achieving the triple aim of improving population health and patient experience at a lower cost per capita. Unfortunately, the inherent tension between outcomes, quality, and cost makes it difficult to strike an optimal balance. Governments and insurers seek cost-containment strategies that do not compromise care quality, while patients expect better health outcomes/personalized treatments and healthcare providers seek full reimbursement for delivering effective and safe treatments.
Value-based healthcare resolves these conflicting objectives by aligning rewards with outcomes and care quality at a population level rather than a transactional one. In VBC, this concept is applied to the financial arrangements between payers, providers, and suppliers to ensure treatments, technologies, and services are paid for when they deliver their expected benefits.
This Viewpoint examines the principles of VBC, its potential benefits, and the challenges associated with its adoption. We present a framework to guide its implementation and highlight early successes through case studies from mature markets such as the US, the UK, and the Netherlands and how they can be applied in emerging markets such as the Kingdom of Saudi Arabia (KSA). By transitioning to a value-driven approach, healthcare systems have been able to improve patient care, optimize resource consumption, and align the competing priorities of payers, regulators, and drug/device manufacturers.
Global healthcare systems are under pressure from rising demand due to aging populations, chronic disease prevalence, and increased use of services. Innovations like gene therapies and advanced diagnostics offer major benefits but strain limited resources. Healthcare expenditure continues to escalate, driven by medical inflation, expensive new treatments, and workforce shortages, as evidenced in many markets (see Figure 1).
High-cost innovations like cell and gene therapies raise tough questions about affordability and access. For example, when the drug sacituzumab govitecan (a treatment for metastatic triple-negative breast cancer) was initially not approved by UK regulator NICE (National Institute for Health and Care Excellence) because of cost concerns, thousands of patients were impacted. Healthcare systems that can tie reimbursement to treatment effectiveness are better able to introduce innovative therapies.
Care quality also varies widely, with inconsistent outcomes across regions and providers, leading to preventable complications and higher costs. Fee-for-service (FFS) models continue to dominate because they’re easier to manage and incent productivity, but they reward volume over value, which fuels inefficiencies and cost escalation.
There is a growing recognition that a fundamental shift must occur to encourage cost-effective interventions while ensuring that quality and patient outcomes remain a priority. With a value-based approach, healthcare systems gain the ability to balance cost containment with the imperative to deliver high-quality, innovative care on a sustainable basis.
In healthcare, value is the degree to which healthcare services contribute to positive health outcomes for patients at the lowest cost while ensuring a positive patient experience and promoting population health. In value-based healthcare, the emphasis is on improving long-term health outcomes rather than episodic interventions. This is measured by metrics such as hospital readmission rates, mortality rates, and patient satisfaction. By aligning financial incentives with these value-driven outcomes, value-based healthcare aims to improve the quality, efficiency, and effectiveness of healthcare services.
Traditionally, reimbursement has been based on an FFS model: providers are compensated for patient visits and procedures rather than the effectiveness of the care provided. Occasionally, some form of outcome or value metric is included, but in general, FFS models lead to unnecessary treatments, fragmented care, and rising healthcare expenditure.
In value-based healthcare, a contract establishes an agreement between payers (e.g., insurance companies), healthcare providers (e.g., hospitals and clinics), and suppliers (e.g., drug and device manufacturers), in which price and payment are tied to clinical or economic results. The key differences are shown in Figure 2.
In summary, VBC:
VBC is applicable to both traditional and new treatments, technologies, and services. VBC models support the objectives of each, taking into account their specific cost and expected patient volumes. For simplicity, we examine three categories, into which any existing or new treatment, technology, or service can be classified (see Figure 3):
In high-demand/moderate-cost scenarios, FFS rewards the volume of services provided, regardless of quality or outcomes. VBC, in contrast, lets healthcare systems standardize clinical pathways, contain costs, and improve care quality. For example, with bundled payments, healthcare providers share financial risk and are thus incented to reduce complications and avoid readmissions.
By aligning incentives between payers and providers, this model promotes efficiency, lowers costs, and ensures high-quality care — shifting the focus from quantity to performance.
In medium-volume/relatively high-cost scenarios, risk-sharing mechanisms help distribute financial and clinical responsibility, ensuring cost-effective care. Additionally, long-term tracking of patient outcomes enables continuous quality improvement and the means to identify best practices that enhance efficiency and effectiveness.
In low-volume/extremely high-cost scenarios (e.g., emerging therapies), there is a significant financial burden on payers. High-cost therapies for unmet needs offer transformative potential but carry long-term uncertainty, posing risks to health systems. VBC ties reimbursement to real-world performance as a way to resolve this issue.
VBC adoption involves a fundamental shift in how healthcare agreements are structured and managed. VBC is more complex than traditional approaches, requiring risk-sharing, stakeholder collaboration, and performance tracking. Contracting frameworks must evolve to accommodate biparty and multiparty agreements, include tracking of real-world evidence, and align financial incentives with clinical/financial results and patient-reported outcomes. Healthcare systems making this transition need a structured framework like the one shown in Figure 4. Each component is described in detail below.
This component sets the foundation for adopting a value-based model by aligning reimbursement with clinical and economic value rather than treatment volume. Factors such as cost, impact on reimbursement structures and associated risk, patient demand, and overall healthcare impact are evaluated to ensure a clear, data-driven rationale for when and where VBC should be implemented.
Traditional cost-benefit assessments may fall short for new treatments, technologies, or services (particularly those with high costs and small patient populations) due to limited long-term data, uncertain real-world outcomes, and/or high per-patient costs. These treatments typically undergo health technology assessments (HTAs) to evaluate factors such as population cohort size, cost-effectiveness compared to standard care, and available alternatives. However, when a clear reimbursement decision cannot be reached, VBC provides a practical pathway forward. By linking payment to actual performance and outcomes in real-world settings, VBC allows payers to manage uncertainty while ensuring patient access to innovation and distributing financial risk between stakeholders.
VBC models can also be applied to existing treatments, technologies, or services where there is potential to standardize clinical pathways and outcomes, contain costs, and improve care quality. This component ensures that VBC is targeted where it can deliver meaningful system-level value, supporting both innovation and sustainability.
This component operationalizes VBC through the structure of individual contracts. It ensures that agreements are actionable, measurable, and adaptable, allowing stakeholders to define performance expectations, allocate risk, and incent outcomes. This component is where strategic objectives are translated into concrete contractual terms:
This component ensures that VBC contracts are managed effectively across their lifecycle. It provides oversight to ensure performance accountability, outcome tracking, and dispute resolution, safeguarding clinical and financial objectives.
Effective governance begins with contract approval and activation, ensuring all pre-conditions are met before performance measurement begins. It includes systems for data monitoring, regular reporting, and performance reviews, based on agreed-upon metrics. Unlike traditional models that track activity, governance under VBC evaluates real-world performance and impact, which directly affects reimbursement.
When issues arise, governance enables timely interventions, whether through contract amendments, remediation plans, or financial recalibration. In the event of disputes or ongoing nonperformance, it provides clear resolution pathways, ensuring contracts remain enforceable and fair. Strong governance builds trust across all parties, promotes transparency, and helps VBC agreements deliver their intended outcomes.
3 VBC models
The US, the UK, and the Netherlands have distinct healthcare systems (private sector–driven model in the US, publicly funded National Health System [NHS] in the UK, and a regulated competition system with mandatory private insurance in the Netherlands). Despite these differences, all three nations have introduced VBC to improve cost-efficiency, care quality, and financial sustainability, though their specific objectives and implementation strategies vary. In the US, VBC is widely used to drive cost containment and quality improvement, shifting from FFS to outcome-based payments to enhance efficiency and care coordination. In the UK, VBC ensures cost-effective NHS spending by linking payments to patient outcomes and provider performance. The Netherlands, with its universal coverage and insurer-led competition, leverages VBC to drive integrated care models, efficiency, and risk-sharing among stakeholders.
Figure A shows how VBC models are applied in the US, the UK, and the Netherlands and their impact on diverse healthcare systems. Model selection depends on cost predictability, outcome certainty, and risk-sharing needs. For example, bundled payments suit high-volume, standardized procedures with clear care pathways; shared savings improve chronic care while lowering provider risk; shared risk balances quality and cost; and CED supports access to innovative treatments while gathering real-world data to inform reimbursement and coverage decisions.
For emerging markets such as KSA, who are looking to transition to VBC, the first step is adopting a structured, outcome-driven framework:
A structured, action-oriented approach is critical for effective VBC implementation. From selecting high-impact treatments to defining eligibility, designing contracts, and building data and governance infrastructure, each step must be clearly defined to ensure alignment, accountability, and impact (see Figure 5).
VBC shifts healthcare reimbursement from paying for treatment volume to paying for positive patient outcomes. Successful implementation requires regulatory support, investment in health informatics, and collaboration between payers, providers, and policymakers:
By Farhan Mirza, Vikas Kharbanda, Marta Kleine, Rajvi Savla, Dany Salameh
cloud technology
Xcalibur Smart Mapping, reconocida como líder mundial en geofísica a...
